Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
PF-04217903 binds to MET and inhibits its activation, resulting in decreased activation of downstream signaling, and potentially resulting in decreased tumor cell growth and migration and increased tumor cell death (PMID: 28599617).
|DrugClasses||MET Inhibitor 56|
|CAS Registry Number||956905-27-4|
|Therapy Name||Drugs||Efficacy Evidence||Clinical Trials|
|CGM097 + Dabrafenib + Navitoclax + PF-04217903||CGM097 Dabrafenib Navitoclax PF-04217903||1||0|
|PF-04217903 + PF-04880594||PF-04217903 PF-04880594||0||0|